SATURDAY 4 SEPTEMBER

16.30 – 18.00
Venue: Amphitheatre Bordeaux

Coordinators: F. Recchia USA, J. Penn USA

Precis
Converging lines of basic and clinical evidence support the role of vascular endothelial growth factor (VEGF) in retinal disease. Indeed, the development and widespread use of anti-VEGF treatments represents one of the best examples of translational medicine. While anti-VEGF therapy for age-related macular degeneration (AMD) has been upheld by several large, prospective, randomized clinical trials, there is no evidence of comparative strength to guide its use in other retinal diseases. The goal of this symposium is to present a critical appraisal of the basic and clinical evidence related to the expanding indications for anti-VEGF therapy. It is hoped that the audience will learn more of the biological rationale, clinical outcomes, advantages, and limitations of this exciting new treatment.

16.30

J. Penn USA
VEGF in human retinal disease: Basic and translational evidence

16.50

S. Rizzo ITALY
Anti-VEGF therapy as a surgical adjuvant

17.02

F. Recchia USA
Anti-VEGF therapy in retinopathy of prematurity

17.14

A. Ciardella ITALY
Anti-VEGF therapy in retinal venous occlusive disease

17.26

P. Hykin UK
Anti-VEGF therapy for diabetic macular edema

17.38

U. Schmidt-Erfurth AUSTRIA
Complications of anti-VEGF therapy: Theoretical and real

17.50

Discussion

18.00

End of session